- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
BriaCell Therapeutics: Process Development Critical to Drug Design Process
BriaCell Therapeutics (TSXV:BCT) (OTCQB:BCTXF) CEO Bill Williams was recently featured in BioPharm International.
BriaCell Therapeutics (TSXV:BCT) (OTCQB:BCTXF) CEO Bill Williams was recently featured in BioPharm International, a medical journal covering the science and business of biopharmaceuticals. The story, written by Cynthia A. Challener, PhD, touches on the importance of process development for startups in the pharmaceutical industry. According to Williams, there are three critical aspects of process development: process development in the production of novel therapeutics, in the design and implementation of clinical trials and in the selection of new drug targets.
“We possess the intellectual resources for both selection of new drug targets and clinical trial design, and have access to the proper expertise and facilities for therapeutic development and drug production.”
According to Williams, BriaCell generally oversees process development for the production of its therapeutics, working with clinical research organizations (CROs) to develop cellular therapies in collaboration with regulatory experts. “It all falls into place based on who possesses the appropriate expertise and access to the corresponding resources,” said Williams.
To read the full story, click here.
Click here to connect with BriaCell Therapeutics (TSXV:BCT) for an Investor Presentation.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.